Novobiocin

In the clinical treatment of Gram-positive bacterial infections, the problem of drug resistance has long restricted the choice of medication. As a representative variety of coumarin antibiotics, novobiocin exerts a bactericidal effect by specifically inhibiting the activity of the B subunit of bacterial DNA gyrase and blocking the DNA replication process. It has definite antibacterial activity against Gram-positive bacteria such as Staphylococcus aureus, Streptococcus pneumoniae and some drug-resistant strains. Clinically, it is mainly used for the treatment of infectious diseases such as pneumonia, sepsis and endocarditis caused by sensitive bacteria, and is mostly used for patient groups who are allergic to penicillin and cephalosporin antibiotics or have drug resistance to them.

At present, the global market size of novobiocin is small, and it is generally in the stage of narrow application. There is no publicly verifiable unified data on market size and growth rate. In terms of competitive landscape, due to the limited clinical use scenarios, the number of global manufacturers is small. After the original research product was withdrawn from the market, the market supply is dominated by compliant generic API and preparations, and the demand side is mainly concentrated in the second-line treatment scenarios of drug-resistant bacterial infections and drug reserve for special populations.

The original research enterprise of novobiocin is Pfizer, and the original research trade name is Albamycin. The core compound patent expired before 1990. The main dosage forms of the original research include 250mg capsules and 500mg injections. The original reference listed drug was once included in the FDA Orange Book and has now been withdrawn from the market. In terms of the domestic market, there is no valid registration number of novobiocin API on the CDE API registration platform at present, and no domestically approved novobiocin preparation products have been found. (Data as of September 2024, please refer to the official CDE website for the latest information)

CATO can provide a full set of novobiocin impurity reference standards. Most products are regularly kept in stock. For in-stock orders placed before 16:00, delivery can be made on the same day. All products meet the requirements of multiple regulatory systems such as Chinese Pharmacopoeia and FDA, and fully meet the full-process needs of API manufacturers in impurity research, quality control and regulatory declaration.